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Abstract
Emergency contraceptives (EC) are a birth control method
that is available to minimize unintended pregnancies that
might result from unprotected intercourse. Several products
are on the market and largely contain levonorgestrel as the
active component, including Plan B One-Step®, Next Choice®,
Next Choice One Dose™ and My Way®. These are labeled as
effective up to 72 hours after intercourse and are available
without a prescription. Another product, Ella™, contains
ulipristal acetate and can be effective up to 120 hours after
intercourse, but does require a prescription. Legislative issues have surrounded these products. At this point in time
only Plan B One-Step® is available to anyone of any gender or
age without a prescription. Ulipristal acetate has been shown
to be more efficacious in reducing pregnancies than the
levonorgestrel most likely due to its effects later in the ovulatory cycle. All of these products have similar side effects and
none of them will terminate an existing pregnancy. Cost issues may influence an individual's choice to use these products. A pharmacist can aid in counseling on the appropriate
selection of a product, timing of administration and methods
for preventive birth control for the future.
Introduction
Emergency contraceptives (EC) are a birth control method
that reduces the likelihood of pregnancy after unprotected
intercourse. Emergency contraceptives are commonly called
"the morning after pill" or "the day after pill" and come in a
variety of different active ingredient and dosage options. In
2001, in the United States, about 50 percent of 6.7 million
pregnancies were unintended, and one in 10 women aged 18
to 24 experienced an unintended pregnancy.2 Unintended
pregnancies are more common among unmarried, lowincome, less educated and minority women. These rates have
remained high in the past two decades, making EC an increasingly popular birth control option. Fifty-three percent
of these unintended pregnancies used contraceptive methods that failed, which includes both a mechanical failure such
as a condom slipping or breaking, as well as an oral contraceptive failure such as missing a dose. 2 Any of these failures
encourage the use of an emergency contraceptive by
women. 1
Because of the high prevalence of these unintended pregnancies, EC options are relevant and need to be understood.
Forty-nine percent of previous EC users attributed their use
of an emergency contraceptive to the nonuse of any other
form of birth control. Comparatively, only 39 percent attributed their use to worry that their regular method had not
worked. One reason the percentages are so high for EC use is
because women rely on health care professionals for infor-

mation about contraceptives, however there is a lack of education about contraceptive methods that could reduce the
usage of EC. In a study done by Kavanaugh et al., it was noted
that among the 63 percent of women that received a Pap test
or pelvic examination in the past year, only 4 percent
reported that they were counseled about EC.3 This lack of
patient counseling in routine visits by female patients has
resulted in an inadequacy of women's knowledge on how to
obtain and safely and effectively use EC.
There are many different options for EC that can be purchased in a pharmacy. One of the most popular options is
levonorgestrel (LNG)-based EC. These include Plan B OneStep®, Next Choice®, Next Choice One Dose™ and My Way®.
Plan B is no longer marketed, but generic versions are still
available. The U.S. Food and Drug Administration (FDA) approved its successor, Plan B One-Step®, in 2009. Plan B OneStep® is a single oral tablet that contains LNG 1.5 mg. Next
Choice® is the generic form of Plan B, which consists of two
oral tablets that contain LNG 0.75 mg each. Next Choice One
Dose™ is the generic form of Plan B One-Step®, one oral tablet that contains LNG 1.5 mg. Similarly, My Way® is one oral
tablet that contains LNG 1.5 mg. A different option is the nonLNG based Ella®. Ella® is the newest form of EC that is also an
oral tablet, and it contains ulipristal acetate (UPA) 30 mg.
Besides the difference in active ingredient, Ella® is currently
available only as a prescription, while Plan B and Next
Choice® can now be sold as over-the-counter (OTC) medications.
Female Ovulation Cycle
In order to understand how both LNG and UPA act in the
body, familiarity with the female hormone cycle is required.
Low progesterone and estrogen levels indicate the beginning
of the ovulation cycle. The hypothalamus then begins to release gonadotropin-releasing hormone (GnRH), which stimulates the release of follicle stimulating hormone (FSH) and
luteinizing hormone (LH) from the pituitary gland. Follicle
stimulating hormone functions to promote several follicles in
the ovary to grow and develop. These maturing follicles produce estrogen, which increases GnRH production, and in turn
increases LH and FSH levels, inducing what is called the LH
surge. Estrogen also stimulates the growth of the uterine lining. When LH and FSH levels reach their highest point, or the
LH peak, LH stimulates the largest of the maturing follicles to
leave the ovary and release its egg. As the egg travels down
the fallopian tube, the follicle, or corpus luteum, produces
progesterone and estrogen. Progesterone, in combination
with limited estrogen levels, decreases the production of
GnRH, LH, and FSH and stimulates the growth of the uterine
lining. These two actions provide a good environment for a
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fertilized egg to implant while preventing other follicles from
being released from the ovary. If the egg is not fertilized
within several days of ovulation, the corpus luteum will
break down, causing a drop in progesterone and estrogen
levels. This drop hinders the growth of the uterine lining,
which will then break down and be removed during menstruation. Gonadotropin-releasing hormone levels then rise
and the cycle begins again. 4
Marketed Emergency Contraception
The most common options on the market for oral EC are Plan
B One-Step® as well as its generic form, Next Choice One
Dose™, both LNG products, and the relatively new product
Ella®, UPA. In general, EC options attempt to slow the ovulation cycle in order to prevent an egg from being fertilized
after unprotected intercourse.s It is thought that LNG can
have some effects on the fusion of sperm to egg, and while
this may be relevant for everyday LNG contraceptive use, the
frequency and dose of LNG EC products do not have a sufficient impact on fusion. When used as an EC, studies have
shown that LNG temporarily inhibits the release of LH, which
prevents the follicle from releasing its egg. However, this LH
prevention only works when the peak in LH levels is greater
than one day away.6 This means that "the ability of LNG to
interfere with the ovulatory process decreases as ovulation
nears."s Finally, while it is suggested that LNG could inhibit
implantation of a fertilized egg on the endometrial lining,
recent studies using dosing similar to EC do not support this
mechanism of action.7
Ella®: A Prescription-Only Option for EC
Ella®, UPA, is an alternative emergency contraception medication and appears to work in a slightly different way than
LNG. Ulipristal acetate is approved for use up to 120 hours
after unprotected intercourse whereas LNG is only approved
for 72 hours after unprotected intercourse.2 Like LNG, UPA
also delays the rupture of the follicle. However, unlike LNG,
UPA has proven to be more effective at later stages in the
ovulatory cycle.6 In a randomized, placebo-controlled,
double-blind, crossover study of 35 women, UPA delayed
ovulation for at least five days in the majority of women, and
in some cases inhibited ovulation for that cycle all together.
These results were supported both when administered before LH levels had begun to rise and during the LH surge, but
before the LH peaks Because UPA is a selective progesterone
receptor modulator (SPRM) it could have another role in
emergency contraception. By acting as a partial agonist to the
progesterone receptors of the endometrial lining and causing
a perceived decrease in progesterone, UPA causes decreased
thickness of the endometrium. The dominant mechanism of
UPA depends on the time of the patient's menstrual cycle.9
The difference in mechanism of action for LNG and UPA regarding the timing of the LH surge is important because "the
immediate pre-ovulatory treatment window... carries a high
probability of conception."8 Consequently, choosing the correct emergency contraception option is vital. Levonorgestrel
and UPA both delay LH from reaching its peak levels, but
UPA seems to delay the peak closer to the time of expected
ovulation compared to LNG.

Recent Regulation Changes with Plan B
There has been a renewed focus on EC with recent changes
in the regulation of EC, most specifically Plan B One-Step®.
The FDA approved the active ingredient, LNG, in 1999 for use
as an EC. In 2006, it became available as an OTC, but could
only be sold to women who were 18 years or older. In 2009,
the FDA expanded the availability of LNG so that it could be
sold to men and also women who were 17 years or older.
Levonorgestrel products were also available to women
younger than 17, as long as they had a prescription for it.2
There was much controversy over legalizing OTC sales of EC,
and the decision was a drawn out process with multiple
court rulings and disagreements between government agencies and departments. The push for making EC available OTC
began in December 2001, when Teva Women's Health filed
an application for Plan B One-Step® to be sold OTC without a
prescription or any age restrictions. On the day this was to
take effect, Kathleen Sebelius, U.S. Health and Human Services Secretary, reversed the decision that required the FDA
to remove restrictions on Plan B One-Step®; five days later,
the FDA also denied a citizen's petition requesting Plan B
One-Step® to be made available OTC. These two decisions left
Plan-B One-Step® only available with the original restrictions, as a prescription. However, on April 5, 2013, Judge
Korman, U.S. District Judge of New York, ordered the FDA to
make all LNG-based contraceptives available OTC, and despite a proposal by the Obama administration to repeal the
order, on April 30, 2013, the FDA partially complied with
Judge Korman's order by making Plan B One-Step® available
OTC but with restrictions that the buyer must be female and
over the age of 15. 10.11 The debate was eventually settled and
the final result was that starting on June 20, 2013, Plan B
One-Step® could be sold to anyone as an OTC product, without a prescription, regardless of age or gender. This decision
meant a wider patient base for EC and less regulation than
was seen with any LNG product in the past. However, the
changes to Plan B One-Step® availability do not apply to any
other LNG-based contraceptives, including Plan B, Next
Choice® and Next Choice One Doser". These other LNG-based
EC are only available behind the pharmacy counter, without
a prescription, for anyone age 17 or older, and can be purchased with a prescription for those under 17. This is only in
effect until Plan B One-Step®'s patent expires in three years.
Then, the makers of Next Choice One Dose"" can file for an
application to make it available OTC without age restrictions.

Comparing Levonorgestrel Products and Ella®
Ingredients and Mechanism of Action
Levonorgestrel
As stated previously, these products contain 1.5 mg LNG:
Next Choice® with two tablets of 0.75 mg LNG each and Plan
B One Step® and Next Choice One Dose™ with one tablet of
1.5 mg LNG. Levonorgestrel acts as an EC by primarily preventing ovulation, preventing fertilization by altering tubal
transport of sperm or egg, and possibly inhibiting implantation by altering the endometrium.6
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Ella®
Ella® contains 30 mg UPA and acts as a selective progesterone receptor modulator with antagonistic and partial agonist
effects at the progesterone receptor, preventing progesterone from binding to its receptor. The primary action of Ella®
is inhibiting ovulation by directly postponing follicular rupture.6.9 Ella® potentially has a second mechanism in that it
may cause endometrial changes to inhibit implantation.6,9
Depending on the phase of the menstrual cycle in which the
drug was administered, Ella® has other dose-dependent effects. A dose in the early luteal phase can decrease the thickness of the endometrium, delay endometrial maturation, and
increase progesterone receptors. A dose in the mid-follicular
phase causes inhibition of folliculogenesis and steroidogenesis, and a dose during the LH peak can delay follicular rupture considerably without interrupting luteinization.9 All
dose-dependent effects described above are specific to the
menstrual phase in which the patient is currently in at the
time of drug administration and all physiological effects are
contributory to Ella®'s use in emergency contraception.

Availability
Levonorgestrel
Levonorgestrel products (Plan B One Step®, Next Choice®,
and Next Choice One Dose™) are available to patients OTC at
local drug stores. The LNG product Plan B that contained two
0. 75 mg LNG tablets is no longer being manufactured or sold.
As previously noted, Plan B One Step® is no longer sold behind the pharmacy counter with the requirement of verifying
identification. Any patient of any age or gender can purchase
Plan B One Step®. However, Next Choice® and Next Choice
One Dose™ still require identification to validate a patient's
age 17 or older for the purchase.

Ella
Unlike LNG, Ella® can only be dispensed to patients with a
valid prescription. Prescriptions can be dispensed in two
ways. First, most pharmacies have Ella® in stock and therefore the medication can be dispensed at the patient's preferred pharmacy. Second, patients can visit KwikMed at ellakwikmed.com or call 855-2ELLARX (855-235-5279) to fill
their prescription. KwikMed is an online service staffed with
licensed physicians to prescribe medications online or over
the phone. Patients without a prescription can also visit this
website or call the Ella-Rx line where they can complete an
online consultation to determine if treatment with Ella® is
appropriate. Clinics that aid young women with unplanned
pregnancies, such as Planned Parenthood, may also carry
Ella®.

Administration
Correct and timely administration of EC is crucial for ensuring maximum efficacy.
Levonorgestrel
Levonorgestrel products can be purchased in boxes containing either one or two tablets: Next Choice® contains two 0.75
mg LNG tablets; Plan B One Step® and Next Choice One
Dose™ contain one 1.5 mg LNG tablet. Patients who chose the
former option should take one tablet within 72 hours of un-
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protected intercourse, followed by the administration of the
second tablet 12 hours later. The latter option is used by administering one tablet within 72 hours of unprotected intercourse or contraceptive failure. If vomiting occurs within one
hour of taking LNG or within two hours of Plan B One Step®,
the dose should be repeated. Patients should be aware that
LNG is only effective within 72 hours of unprotected intercourse and immediate administration of the drug is encouraged for maximum efficacy.

Ella®
Ella® contains one 30 mg tablet of UPA, which can be taken
within 120 hours (five days) of unprotected intercourse or
suspected contraceptive failure. The dose is to be repeated if
vomiting occurs within three hours of administration. Ella®
can be taken with or without food and at any time during the
menstrual cycle.

Efficacy ofLevonorgestrel versus Ella®
In general, EC are most effective during the days directly
prior to ovulation, considering intercourse during this time
frame has the highest probability of pregnancy.a Ovulation
must be prevented for at least five days, based upon the spermatozoa lifespan in the female genital tract of 120 hours.a.9 In
two double-blinded, randomized, multicenter studies, the
widely used dose of LNG 1.5 mg reduced the expected pregnancy rate without emergency contraception of 8 percent to
approximately 1 percent.1 2 However, previous studies have
agreed that LNG's ability to prevent ovulation decreases as
ovulation nears. After the LH surge is triggered during the
ovulatory process, LNG does not appear to prevent the follicle from rupturing.a Researchers saw an advantage of creating an EC that would be effective in delaying ovulation for
five days, because LNG had no contraceptive effects in the
presence of LH. In an analysis of pooled data from three randomized trials comparing EC efficacy, 48 cycles were treated
with LNG, 34 cycles with UPA and 50 cycles with placebo. It
was found that UPA "was effective in preventing follicle rupture in the five days following treatment, even when administered at the time of the LH surge (UPA 79%, LNG 14%, and
placebo 10%)."a Moreover, women who took UPA were significantly less likely to become pregnant than those receiving
LNG [Odds ratio (OR): 0.55, 95% Confident indicator (CI):
0.32-0.93].a As previously emphasized, timely administration
of these EC is critical for their highest efficacy. Ulipristal acetate and LNG administered within 24 hours of unprotected
intercourse or failed contraception showed lower pregnancy
rates. Results showed a two-thirds lower risk for pregnancy
in women who took UPA over LNG within the 24 hours
(OR 0.35, 95% CI: 0.11-0.93).a
Side Effects, Warnings and Precautions,
Contraindications
Levonorgestrel and UPA share very similar side effects,
warnings, contraindications and drug interactions. For LNG,
the most common side effects documented in more than
10 percent of women in clinical trials include: heavier menstrual bleeding (30.9%), nausea (13.7%), lower abdominal
pain (13.3%), fatigue (13.3%), headache (10.3%), dizziness
(9.6%) and breast tenderness (8.2%).12 Side effects for UPA
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seen in more than 5 percent of women in clinical trials include: headache (18%), abdominal pain (12%), nausea
(12%), dysmenorrhea (9%), fatigue (6%) and dizziness
(5%).9 For both medications, there is a risk of ectopic pregnancy. One sign of ectopic pregnancy is lower abdominal
pain after administration of EC, and patients who experience
this symptom should seek medical attention immediately.
Moreover, LNG and UPA do not terminate an existing pregnancy. Patients taking medications or herbal products that
induce CYP3A4 may be hindering the efficacy of these EC.
Finally, both medications are contraindicated in women with
known or suspected pregnancy.
Cost
Unintended pregnancies in the United States are a prevalent
public health issue and associated medical costs are about $5
billion since estimated in 2002.2 A study conducted in 2012,
used a decision analytic model to make comparisons of the
use of LNG to UPA as EC for the prevention of unintended
pregnancies. The study concluded that UPA would be a costeffective option for preventing unintended pregnancies, indicating that "utilizing UPA instead of LNG would result in
37,589 fewer unintended pregnancies per 4,176,572 estimated U.S. annual EC uses (UPA failed to prevent 54,295
unintended pregnancies; LNG failed to prevent 91,884 unintended pregnancies) and a societal savings of $116.3 million
annually." 2 However, from a more local standpoint, patients
can purchase these products OTC, except for UPA. According
to a 2013 survey conducted by the American Society for
Emergency Contraception, the average price and price
ranges for brand (Plan 8 One-Step®), generic (Next Choice®)

and UPA widely vary (Table 1).13 Ulipristal acetate's cost may
vary depending on the patient's insurance, but it can be purchased via KwikMed service at ella-kwikmed.com with free
shipping.9 While these results displayed a wide range of
prices, cost still remains a barrier for those seeking EC.
Patient Counseling
Patients having contraceptive failure or inconsistent contraceptive use should be counseled on correct and consistent
forms of birth control to avoid unintended pregnancies. The
combination of contraceptive failure with inconsistent or
incorrect use is the cause of 48 percent of the 3.1 million unintended pregnancies.14 Emergency contraceptives are not
indicated for terminating existing pregnancies, therefore
women with suspected pregnancies should not use these
medications. When patients decide they would like to use
EC, emphasize the importance of timely and correct administration. Levonorgestrel-based products are all effective
within three days following unprotected intercourse or failed
contraception, while Ella® is effective within five days. Taking these medications as soon as possible or "the morning
after" is ideal for maximum efficacy. Patients should be counseled on potential side effects such as nausea and headache,
and if patients are experiencing lower abdominal pain three
to five weeks after taking EC, they should be instructed to
seek medical attention immediately with the concern of ectopic pregnancy. Patients who miss menses for more than
seven days after its expected date should contact their health
care provider, as pregnancy may be a possibility. Continual
users of EC should be urgently informed that these medications are not a regular form of birth control, nor do they pro-

Table 1. Emergency Contraceptive Product Comparison
Plan-B One Step®

Next Choice®

Next Choice One
Dose™

Ella®

Average Cost*

$48.65

$40.29

$41.63

Insurance Dependent
or
Available on K wik Med:
$40

Price Range*

$32-65

NIA

$26-62

NIA

Number of Tablets

I

2

I

1

Active Drug

LNG

LNG

LNG

UPA

Strength

1.5 mg

0.75 mg

1.5 mg

30mg

Administration Timeline

Within 72 hours (3
days) of unprotected
intercourse

First dose within 72
hours (3 days) ofunprotected intercourse;
Second dose 12 hours
following first dose

Within 72 hours (3 days)
of unprotected
intercourse

Within 120 hours
(5 days) of unprotected
intercourse

Availability

OTC

OTC (must be 2: 17 years
old)
Rx if< 17 years old

OTC (must be 2: 17 years
old)
Rx if < 17 years old

Rx only

*Prices are averages from chain store pharmacies
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tect against human immunodeficiency virus (HIV) infections
or other sexually transmitted diseases. To ensure best practices from our patients and efficacious outcomes, it is critical
that pharmacists ask relevant questions and provide information for the betterment of patients' health.

Conclusion
Emergency contraceptives are a quickly changing and currently underutilized aspect of public health. Unintended
pregnancies are occurring at high rates, demonstrating that
the need for education and information about EC in the
population is not adequately being met by health care providers. With a more extensive understanding of how, when
and why to use a particular EC product, patients can make
their own decisions about their need for EC. With multiple
options of EC on the market, including LNG and UPA, there
are several important decisions to be made by the patient. As
shown by recent regulation changes, the availability of LNG
products are rapidly changing in regard to age and OTC
status. Awareness of these changes is vital in aiding a patient
in their final EC selection. These decisions also include cost
comparison, side effect risk/benefit evaluations and determining which will be more effective in their specific situation. All of these decisions require health care providers,
especially pharmacists, to understand the drugs' mechanisms
to prevent pregnancy. Status and availability of EC products
may be changing, but the role of the pharmacist is not. In
light of new products entering the market, such as UPA,
counseling and education is necessary now more than ever.
Understanding the similarities and differences between two
of the major EC options gives pharmacists a huge opportunity for education to greatly influence patient health.
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